Please wait...
About This Project
OncoSynergy, Inc.
The Ebola outbreak in west Africa has been declared a global emergency by the WHO with over 1,000 victims and no approved therapies. OncoSynergy is developing a readily manufactured experimental cancer drug, OS2966, which coincidentally targets the receptor hijacked by ebola to infect cells. This project aims to demonstrate that OS2966 inhibits ebola infection of human cells thus providing the impetus for expediting OS2966 for treatment of ebola.
Recent Lab Notes From This Project
Browse Other Projects on Experiment
Related Projects
Household Composting Toilets for Agriculture in Malawi
Ninety percent of Malawi does not have access to improved sanitation. 90% of the people also work in agriculture...
Enhancing hydrogen production in Rhodobacter sphaeroides for use as an economically viable biofuel
We aim to create a novel biological chassis that exploits both fermentative and photosynthetic pathways for...
